Unexpected Immune Biomarker Separation by Recorded Long COVID Status in an Exploratory Cross-Sectional Study
Diagnostics · 11.11.2026 · 16 (22) · 3722
DOI: 10.3390/diagnostics16223722 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Diagnostics, online erschienen am 11.11.2026. Verfasst von Yuka Yamagishi und 3 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Public Interest Incorporated Foundation Kenzo Suzuki Memorial Foundation for Medical Science Research.
Abstract (Originalsprache)
Background
Long COVID is clinically and immunologically heterogeneous. We describe unexpected biomarker separation between recorded groups and limitations that prevent a disease-specific interpretation.
Methods
This exploratory cross-sectional secondary analysis included 191 post-COVID records: 158 labeled long COVID and 33 originally designated “No adverse events.” The comparator designation did not establish a clinically verified absence of post-COVID sequelae. Eight biomarkers were evaluated after correction of confirmed reporting errors at common assay lower limits. Analyses included rank-based comparisons, Firth penalized logistic regression, internal resampling, censoring sensitivity analyses and exploratory clustering.
Results
Seven biomarkers were higher in the recorded long COVID group (all false-discovery-rate q < 0.001). Apparent areas under the receiver operating characteristic curve (AUCs) were 0.9942 for CXCL9 and 0.9914 for IL-6. The seven-marker model had an apparent AUC of 1.0000 and a mean cross-validated AUC of 0.9989. CXCL9 was at or below the reporting limit in 30/33 comparator records versus 1/158 long COVID records. All individual coefficients in the full model had 95% profile intervals including the null. Clustering did not establish distinct biological subtypes.
Conclusions
The unexpectedly strong separation is a hypothesis-generating observation requiring independent investigation. Incomplete verification of group definitions and sampling times limits disease-specific interpretation. These findings do not establish a long COVID-specific immune signature or a clinically applicable diagnostic test.
Förderung
- Public Interest Incorporated Foundation Kenzo Suzuki Memorial Foundation for Medical Science Research
Zitieren
APA
Yamagishi, Y., Takahashi, S., Kunishima, H., & Mikamo, H. (2026). Unexpected Immune Biomarker Separation by Recorded Long COVID Status in an Exploratory Cross-Sectional Study. Diagnostics, 16(22), 3722. https://doi.org/10.3390/diagnostics16223722
Vancouver
Yamagishi Y, Takahashi S, Kunishima H, Mikamo H. Unexpected Immune Biomarker Separation by Recorded Long COVID Status in an Exploratory Cross-Sectional Study. Diagnostics. 2026;16(22):3722. doi:10.3390/diagnostics16223722
BibTeX
@article{Yamagishi2026,
author = {Yamagishi, Yuka and Takahashi, Satoshi and Kunishima, Hiroyuki and Mikamo, Hiroshige},
title = {Unexpected Immune Biomarker Separation by Recorded Long COVID Status in an Exploratory Cross-Sectional Study},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {22},
pages = {3722},
doi = {10.3390/diagnostics16223722}
}
EUVIMED